The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter, phase III trial (RADIANT-3).
Jonathan Strosberg
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Jeremie Lincy
Employment or Leadership Position - Novartis
Robert Winkler
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Edward Wolin
Consultant or Advisory Role - Novartis